List view / Grid view
15 July 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
Recently there has been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the second of a three-part series, Dr Raminderpal Singh presents an example of usage of ChatGPT, which demonstrates how accessible LLMs have become for lab scientists.
14 May 2025 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
AI is reshaping drug discovery – but not without resistance. In this two-part conversation, André França and Eli Pollock share honest insights about the real barriers to AI adoption in life sciences and how embedding domain expertise into AI workflows might be the key to unlocking its full potential.
26 May 2025 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
As AI reshapes scientific work, two founders debate how best to build tools scientists can trust — should we embed expertise into the model or the team? From agent-powered labs to hypothesis-generating machines, the future of drug discovery is being reimagined right now.
ON-DEMAND | By Drug Target Review
Manual processes are slowing down your lab. AI and automation can change that, if you know how to use them. In this free webinar, Dr Raminderpal Singh breaks down the technologies, data strategies and tools transforming early drug discovery, so you can stop guessing and start innovating.
24 September 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective.
20 June 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the third of a three-part series – Dr Raminderpal Singh touches on the decisions that need…
24 June 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
Recently there have been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they…
24 July 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
There have been a slew of announcements over the past few months from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the third of a three-part series, Dr Raminderpal Singh presents some pragmatic guidelines for scientists in accessing and obtaining value from LLMs.
26 August 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
14 October 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
In this article, Dr Raminderpal Singh speaks to Neil Wilkie of Mironid Ltd. for a biotech CEO’s perspective on the transformative potential of AI, and the importance of bridging communication gaps between scientific and technical teams to drive innovation and efficiency in the pharmaceutical industry.
24 October 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
In this article, Dr Raminderpal Singh speaks to Janette Thomas of Five Alarm Bio for a biotech CEO’s perspective on the complexity of data faced by both large and small biotechs. Janette is on a mission to develop drugs targeting the chronic diseases associated with ageing. She shares her insights…
14 January 2025 | By Dr Raminderal Singh (Hitchhikers AI and 20/15 Visioneers, Nina Truter
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
14 February 2025 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers), Nina Truter
Drug discovery scientists develop and test complex hypotheses using data and expertise, and build workflows to support this. In this third and final article, Dr Raminderpal Singh and Nina Truter summarise the tools used in the scientific workflow – and include key considerations.
14 August 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
24 May 2024 | By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the second of a three-part series – Dr Raminderpal Singh touches on methods that are being…
